Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV078 in TSC Refractory Epilepsy
NCT07680322Phase 2Not yet recruiting
- Sponsor
- Aeovian Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of AV078 in tuberous sclerosis complex (TSC), epilepsy, sponsored by Aeovian Pharmaceuticals. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
AV078
03
Conditions
tuberous sclerosis complex (TSC)epilepsy
Beyond the preview
Go deeper on NCT07680322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680322.